Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
13 September 2017 - 10:05PM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
immunotherapy company focused on the development of treatments for
autoimmune/inflammatory diseases and cancer, announced today that
the company will present at the Ladenburg Thalmann 2017 Healthcare
Conference in New York on Tuesday, September 26, 2017, at 10:00am
Eastern Time.
A live webcast of the presentation will be available online from
the investors relations page of the company’s website at
https://ir.alpineimmunesciences.com/events. After the webcast, an
archive of the presentation will be available on the company
website for 90 days.
About Alpine Immune Sciences, Inc. Alpine Immune
Sciences, Inc. is focused on developing novel protein-based
immunotherapies using its proprietary Variant Ig Domain™ vIgD™
platform technology. The vIgD platform is designed to interact with
multiple targets, including many present in the immune synapse.
Alpine’s vIgDs are developed using a process known as directed
evolution, which produces proteins capable of either enhancing or
diminishing an immune response and thereby may potentially apply
therapeutically to cancer, autoimmune, and inflammatory diseases.
Alpine has also developed TIP™ technology, based on the vIgD
platform, to potentially enhance engineered cellular therapies. In
October 2015, Alpine signed a worldwide research and license
agreement with Kite Pharma, Inc. (NASDAQ:KITE) for up to $535
million in up front and potential milestone payments plus royalties
on resulting sales. For more information visit
www.alpineimmunesciences.com/.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913006360/en/
For Alpine Immune Sciences, Inc.Investors:Courtney Dugan,
212-257-6723cdugan@purecommunications.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024